Case number 1:22-cv-00199
Astellas US LLC et al v. Curia Missouri Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| May 5, 2023 | 100 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,403,567; US RE 47,301 E; US 8,524,883; US 8,106,183. (Attachments: # 1 Notice of Dismissal)(kmd) (Entered: 05/05/2023) (Main Document) (1) |
| May 5, 2023 | 100 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,403,567; US RE 47,301 E; US 8,524,883; US 8,106,183. (Attachments: # 1 Notice of Dismissal)(kmd) (Entered: 05/05/2023) (Notice of Dismissal) (2) |
| May 4, 2023 | 99 | NOTICE of Voluntary Dismissal by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc. as to Curia Missouri, Inc. and Curia Global, Inc. (Oakes, Robert) (Entered: 05/04/2023) (2) |
| Apr 27, 2023 | 97 | STIPULATION TO EXTEND TIME Proposed Protective Order and Disclosure of Asserted Claims and Infringement Contentions and Accompanying Document Production to May 8, 2023 - filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 04/27/2023) (2) |
| Apr 27, 2023 | 98 | SO ORDERED, re 97 STIPULATION TO EXTEND TIME Proposed Protective Order and Disclosure of Asserted Claims and Infringement Contentions and Accompanying Document Production to May 8, 2023, filed by Gilead Sciences, Inc., Astellas Pharma US, Inc., Astellas US LLC. Signed by Judge Colm F. Connolly on 4/27/2023. (kmd) (Entered: 04/27/2023) (2) |
| Apr 24, 2023 | 96 | SO ORDERED, re 95 STIPULATION TO EXTEND TIME Protective Order to May 1, 2023, filed by Gilead Sciences, Inc., Astellas Pharma US, Inc., Astellas US LLC. Signed by Judge Colm F. Connolly on 4/24/2023. (kmd) (Entered: 04/24/2023) (2) |
| Apr 21, 2023 | 95 | STIPULATION TO EXTEND TIME Protective Order to May 1, 2023 - filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 04/21/2023) (2) |
| Apr 14, 2023 | 94 | STIPULATION TO EXTEND TIME Proposed Protective Order and Disclosure of Asserted Claims and Infringement Contentions and Accompanying Document Production to April 24, 2023 and May 1, 2023 - filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 04/14/2023) (2) |
| Mar 31, 2023 | 93 | SO ORDERED, re 92 STIPULATION TO EXTEND TIME Protective Order to April 17, 2023, filed by Gilead Sciences, Inc., Astellas Pharma US, Inc., Astellas US LLC. Signed by Judge Colm F. Connolly on 3/31/2023. (kmd) (Entered: 03/31/2023) (2) |
| Mar 30, 2023 | 92 | STIPULATION TO EXTEND TIME Protective Order to April 17, 2023 - filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 03/30/2023) (2) |
| Mar 28, 2023 | 90 | NOTICE OF SERVICE of Plaintiffs' Fed. R. Civ. P. 26(a)(1) Initial Disclosures filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc..(Oakes, Robert) (Entered: 03/28/2023) (2) |
| Mar 28, 2023 | 91 | NOTICE OF SERVICE of Defendants' Fed. R. Civ. P. 26(a)(1) Initial Disclosures filed by Curia Global, Inc., Curia Missouri Inc..(Viceconte, Christopher) (Entered: 03/28/2023) (2) |
| Mar 27, 2023 | 89 | NOTICE OF SERVICE of Plaintiffs First Set of Interrogatories (Nos. 1-15) and First Set of Requests for Production of Documents and Things (Nos. 1-69) filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc..(Oakes, Robert) (Entered: 03/27/2023) (2) |
| Mar 23, 2023 | 88 | SCHEDULING ORDER: Joinder of Parties due by 10/27/2023. Amended Pleadings due by 10/27/2023. Fact Discovery completed by 12/15/2023. Expert Discovery due by 6/10/2024. Dispositive Motions due by 6/25/2024. Answering Brief due 7/9/2024. Reply Brief due 7/16/2024. Joint Claim Construction Brief due by 11/6/2023. A Markman Hearing is set for 12/5/2023 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 9/12/2024. A Final Pretrial Conference is set for 10/16/2024 at 03:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Jury Trial is set for 10/21/2024 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 3/23/2023. (nmf) (Entered: 03/23/2023) (29) |
| Mar 22, 2023 | 87 | PROPOSED ORDER Scheduling Order for Non-Hatch-Waxman Patent Cases in Which Infringement is Alleged by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 03/22/2023) (29) |
| Mar 13, 2023 | 86 | NOTICE of Intent to Request Redaction by Robert M. Oakes re 81 Transcript,, (Oakes, Robert) (Entered: 03/13/2023) (2) |
| Mar 8, 2023 | 85 | [SEALED] MEMORANDUM ORDER regarding D.I. 72 MOTION to Lift Stay. Signed by Judge Christopher J. Burke on 3/8/2023.This order has been emailed to local counsel. (dlb) (Entered: 03/08/2023) (0) |
| Mar 7, 2023 | 84 | Letter to The Honorable Christopher J. Burke from Christopher Viceconte regarding Further Opposition to Plaintiffs' Request to Lift Stay Pending Case Dispositive Motion to Dismiss - re 82 Letter. (Viceconte, Christopher) (Entered: 03/07/2023) (3) |
| Mar 6, 2023 | 81 | Official Transcript of teleconference held on February 27, 2023 before Judge Christopher Burke. Court Reporter/Transcriber Bonnie Archer,Email: bonnie_archer@ded.us.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter/Transcriber before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 3/27/2023. Redacted Transcript Deadline set for 4/6/2023. Release of Transcript Restriction set for 6/5/2023. (Archer, Bonnie) (Entered: 03/06/2023) (0) |
| Mar 6, 2023 | 82 | Letter to Honorable Christopher J. Burke from Robert M. Oakes regarding Motion to Lift Stay - re 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, , 81 Transcript,,. (Attachments: # 1 Exhibit A)(Oakes, Robert) (Entered: 03/06/2023) (Main Document) (1) |
| Mar 6, 2023 | 83 | ORAL ORDER: The Court, having reviewed Plaintiffs' March 6, 2023 letter, (D.I. 82), hereby ORDERS that Defendants shall, if they wish to, file a responsive letter of no more than two single-spaced pages by no later than close of business on March 7, 2023. The Court will plan to promptly resolve the pending motion to stay thereafter. Ordered by Judge Christopher J. Burke on 3/6/2023. (dlb) (Entered: 03/06/2023) (0) |
| Mar 6, 2023 | 82 | Letter to Honorable Christopher J. Burke from Robert M. Oakes regarding Motion to Lift Stay - re 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, , 81 Transcript,,. (Attachments: # 1 Exhibit A)(Oakes, Robert) (Entered: 03/06/2023) (Exhibit A) (30) |
| Jan 24, 2023 | 80 | ORAL ORDER Setting Teleconference: The Court hereby ORDERS that a telephone conference to hear argument on Plaintiffs' pending Motion to Lift the Stay, (D.I. 72), is set for February 27, 2023 at 11:00 a.m. before Judge Christopher J. Burke. By no later than February 21, 2023, the parties shall jointly provide the Court's Courtroom Deputy, Ms. Benyo, with a dial-in number via email to use for the call. Ordered by Judge Christopher J. Burke on 1/24/2023. (dlb) (Entered: 01/24/2023) (0) |
| Jan 20, 2023 | 78 | REDACTED VERSION of 76 Reply Brief by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 01/20/2023) (11) |
| Jan 20, 2023 | 79 | REQUEST for Oral Argument by Curia Global, Inc., Curia Missouri Inc. re 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, . (Viceconte, Christopher) (Entered: 01/20/2023) (2) |
| Jan 18, 2023 | 77 | REQUEST for Oral Argument by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc. re 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, . (Oakes, Robert) (Entered: 01/18/2023) (2) |
| Jan 13, 2023 | 76 | [SEALED] REPLY BRIEF re 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 01/13/2023) (0) |
| Jan 6, 2023 | 75 | ANSWERING BRIEF in Opposition re 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, filed by Curia Global, Inc., Curia Missouri Inc..Reply Brief due date per Local Rules is 1/13/2023. (Attachments: # 1 Exhibit A, # 2 Certificate of Compliance)(Viceconte, Christopher) (Entered: 01/06/2023) (Main Document) (23) |
| Jan 6, 2023 | 75 | ANSWERING BRIEF in Opposition re 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, filed by Curia Global, Inc., Curia Missouri Inc..Reply Brief due date per Local Rules is 1/13/2023. (Attachments: # 1 Exhibit A, # 2 Certificate of Compliance)(Viceconte, Christopher) (Entered: 01/06/2023) (Exhibit A) (17) |
| Jan 6, 2023 | 75 | ANSWERING BRIEF in Opposition re 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, filed by Curia Global, Inc., Curia Missouri Inc..Reply Brief due date per Local Rules is 1/13/2023. (Attachments: # 1 Exhibit A, # 2 Certificate of Compliance)(Viceconte, Christopher) (Entered: 01/06/2023) (Certificate of Compliance) (2) |
| Dec 29, 2022 | 73 | ORDER REFERRING MOTION: 72 MOTION to Lift Stay referred to Magistrate Judge Christopher J. Burke. Signed by Judge Colm F. Connolly on 12/29/2022. (nmf) (Entered: 12/29/2022) (1) |
| Dec 29, 2022 | 74 | REDACTED VERSION of 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5)(Oakes, Robert) (Entered: 12/29/2022) (Main Document) (13) |
| Dec 29, 2022 | 74 | REDACTED VERSION of 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5)(Oakes, Robert) (Entered: 12/29/2022) (Exhibit 1) (3) |
| Dec 29, 2022 | 74 | REDACTED VERSION of 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5)(Oakes, Robert) (Entered: 12/29/2022) (Exhibit 2) (30) |
| Dec 29, 2022 | 74 | REDACTED VERSION of 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5)(Oakes, Robert) (Entered: 12/29/2022) (Exhibit 3) (3) |
| Dec 29, 2022 | 74 | REDACTED VERSION of 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5)(Oakes, Robert) (Entered: 12/29/2022) (Exhibit 4) (3) |
| Dec 29, 2022 | 74 | REDACTED VERSION of 72 MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5)(Oakes, Robert) (Entered: 12/29/2022) (Exhibit 5) (6) |
| Dec 22, 2022 | 72 | [SEALED] MOTION to Lift Stay re 71 Oral Order,,,,,,,,,,,,,,,,,,,, - filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Text of Proposed Order)(Oakes, Robert) (Entered: 12/22/2022) (0) |
| Jul 14, 2022 | 71 | ORAL ORDER: The Court, having reviewed Defendants Curia Missouri, Inc. and Curia Global, Inc. ("Defendants" or "Curia") motion to stay discovery ("Motion"), (D.I. 55 ), and the briefing related thereto, (D.I. 54; D.I. 59; D.I. 60; D.I. 66; D.I. 68), having considered the three stay-related factors, and having heard argument on the Motion on June 27, 2022, hereby ORDERS that the Motion is GRANTED-IN-PART in the manner set out below.: (1) With regard to the first "simplification" factor, on the one hand, if Defendants' pending motion to dismiss is resolved entirely in Defendants' favor, it would be case dispositive, and it would simplify this case to the greatest degree possible. On the other hand, the Court has to consider "all of the possible outcomes of the... inquiry that the case would be stayed in favor of -- not just the potential outcome most favorable to the party seeking the stay." Kaavo Inc. v. Cognizant Tech. Sols. Corp., Civil Action No. 14-1192-LPS-CJB, Civil Action No. 14-1193-LPS-CJB, 2015 WL 1737476, at *2 (D. Del. Apr. 9, 2015) (emphasis omitted). Were the Motion denied in its entirety, little efficiency gain from a stay would be realized. Id. And because in order to have the entire case dismissed, Defendants need to prevail on two different sets of legal arguments, (see D.I. 26), it might be said that Defendants have a bit of an uphill climb (just from a purely statistical or odds-based perspective) in having the Motion resolved in a way that would entirely eliminate the need for this case to move forward. In light of this, the simplification factor is about neutral. Cf. Shure, Inc. v. Clearone, Inc., Civil Action No. 19-1343-RGA-CJB, D.I. 54 (D. Del. Nov. 1, 2019).; (2) With regard to the second "status of the litigation" factor, this surely supports Defendants' Motion, as we are early in the case, fact discovery has not gotten started, and the Court has not yet expended an undue amount of resources on the case. (D.I. 54 at 2; D.I. 59 at 3).; (3) As for the third "undue prejudice" factor, it favors Defendants, at least right now. As Defendants note, "Plaintiffs do not allege that Curia is presently engaging in any patent infringement." (D.I. 54 at 2; see also D.I. 59 at 4 (Plaintiffs asserting that they have "alleged infringement against Curia for its regadenoson AP, including past and future infringement"); D.I. 60 at 2) Count I of the First Amended Complaint ("FAC") alleges past infringement of the now-expired '567 patent. (D.I. 18 at 10-12; D.I. 54 at 2) And Counts II-IV allege that Defendants will infringe the '183, '301, and '883 patents in the future, if Hospira makes a commercial launch of its ANDA product using Curia's regadenoson. (D.I. 18 at 13-24; D.I. 54 at 2) Even if it can be said that Plaintiffs and Curia might "compete" in the market for certain drug products, (D.I. 59 at 2; D.I. 60 at 2), if no harm in the form of infringement is currently occurring, then the Court does not see how a stay will unduly prejudice Plaintiffs. To be sure, there will be some delay in the case until the motion to dismiss is decided, but delay "does not, by itself, amount to undue prejudice." Ever Win Int'l Corp. v. Radio Shack Corp., 902 F. Supp. 2d 503, 509 (D. Del. 2012) (internal quotation marks and citations omitted).; (4) So as of right now, two of the stay-related factors favor Defendants, and it makes sense, at this stage, to "stay discovery while [the District Court] evaluat[es] a motion to dismiss, where, if the motion is granted [in its entirety], discovery would be futile." Mann v. Brenner, 375 F. App'x 232, 239 (3d Cir. 2010).; (5) That said, the calculus would change if future events occur that lead Plaintiffs to have a reasonable belief that irreparable harm from patent infringement is occurring. In that event, Plaintiffs may want to file a preliminary injunction motion in this case against Curia, and nothing in the Court's Order today is meant to prohibit them from doing so. Cf. Belden Techs. Inc. v. Superior Essex Commc'ns LP, Civ. No. 08-63-SLR, 2010 WL 3522327, at *3 (D. Del. Sept. 2, 2010) (noting that the filing of a preliminary injunction motion can indicate that the parties are direct competitors, or that undue prejudice would befall the movant in the event of a stay).; and (6) Therefore, Defendants' Motion is GRANTED-IN-PART and the case is STAYED, with the caveat that the stay will not impact Plaintiffs' future ability to file a preliminary injunction motion in this case and pursue that motion, if Plaintiffs later determine that there is a Rule 11 basis to support the filing of such a motion. And of course, Plaintiffs can always otherwise move to lift the stay if they think future events warrant such a motion. Ordered by Judge Christopher J. Burke on 7/14/22. (mlc) (Entered: 07/14/2022) (0) |
| Jul 8, 2022 | 70 | REDACTED VERSION of 66 Letter, to Honorable Christopher J. Burke by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Oakes, Robert) (Entered: 07/08/2022) (Main Document) (2) |
| Jul 8, 2022 | 70 | REDACTED VERSION of 66 Letter, to Honorable Christopher J. Burke by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Oakes, Robert) (Entered: 07/08/2022) (Exhibit A) (8) |
| Jul 8, 2022 | 70 | REDACTED VERSION of 66 Letter, to Honorable Christopher J. Burke by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Oakes, Robert) (Entered: 07/08/2022) (Exhibit B) (7) |
| Jul 8, 2022 | 70 | REDACTED VERSION of 66 Letter, to Honorable Christopher J. Burke by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Oakes, Robert) (Entered: 07/08/2022) (Exhibit C) (4) |
| Jul 7, 2022 | 69 | REDACTED VERSION of 68 Letter, to The Honorable Christopher J. Burke from Christopher Viceconte regarding Further Support of Motion to Stay by Curia Global, Inc., Curia Missouri Inc.. (Viceconte, Christopher) (Entered: 07/07/2022) (2) |
| Jun 30, 2022 | 68 | [SEALED] Letter to The Honorable Christopher J. Burke from Christopher Viceconte regarding Further Support of Motion to Stay - re 55 MOTION to Stay re 54 Letter, to The Honorable Christopher J. Burke from Christopher Viceconte Requesting a Stay Pending the Outcome of Curia's Case Dispositive Motion to Dismiss, 66 Letter,. (Viceconte, Christopher) (Entered: 06/30/2022) (0) |
| Jun 29, 2022 | 67 | Letter to Honorable Christopher J. Burke from Robert M. Oakes regarding Oral Order regarding motion to dismiss - re 65 Oral Order,,,,. (Oakes, Robert) (Entered: 06/29/2022) (1) |
| Jun 28, 2022 | 65 | ORAL ORDER: With regard to yesterday's teleconference concerning the pending motion to stay, (D.I. 55), it strikes the Court that a key issue motivating each side to advocate either for or against the grant of that motion is the fact that it may take a substantial period of time for Chief Judge Connolly to be in a position to resolve the pending motion to dismiss, (D.I. 25), in light of the substantial nature of his docket. Therefore, by no later than the close of business on June 29, 2022, the parties should file a joint letter indicating whether they would jointly agree to consent to Judge Burke resolving the pending motion to dismiss (if the parties jointly consent, Judge Burke will commit to resolving the motion to dismiss no later than 30 days from the filing of the consent form). To the extent the parties do not jointly agree to consent, they should simply state that "The parties do not jointly agree to consent to Judge Burke resolving the pending motion to dismiss" (without indicating which side did or did not agree). Ordered by Judge Christopher J. Burke on 6/28/2022. (dlb) (Entered: 06/28/2022) (0) |
| Jun 28, 2022 | 66 | [SEALED] Letter to Honorable Christopher J. Burke from Robert M. Oakes regarding Curia's Motion to Stay - re 55 MOTION to Stay re 54 Letter, to The Honorable Christopher J. Burke from Christopher Viceconte Requesting a Stay Pending the Outcome of Curia's Case Dispositive Motion to Dismiss. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Exhibit C)(Oakes, Robert) (Entered: 06/28/2022) (0) |
| Jun 24, 2022 | 64 | ORAL ORDER: The Court, having considered Plaintiffs' Notice Regarding Intent to Have Newer Attorney Participate in Argument Regarding Curia's Motion to Stay, (D.I. 62), and pursuant to the Court's Standing Order Regarding Courtroom Opportunities for Newer Attorneys, hereby confirms that: (1) it will hear argument on the relevant motion on June 27, 2022 at 11:45 am via teleconference; (2) it will ensure that the parties have at least 60 minutes of argument collectively; and (3) it will permit more experienced counsel for Plaintiffs to assist when appropriate. Ordered by Judge Christopher J. Burke on 6/24/22. (mlc) (Entered: 06/24/2022) (0) |
| Jun 23, 2022 | 62 | NOTICE of Intent to Have Newer Attorney Participate in Argument Regarding Curia's Motion to Stay by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc. re 56 Order Setting Hearing on Motion,,,, (Oakes, Robert) (Entered: 06/23/2022) (3) |
| Jun 23, 2022 | 63 | MOTION for Pro Hac Vice Appearance of Attorney Ryan Petty - filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 06/23/2022) (4) |
| Jun 15, 2022 | 61 | REDACTED VERSION of 60 Letter, to The Honorable Christopher J. Burke from Christopher Viceconte regarding Reply Brief Requesting a Stay Pending the Outcome of Curia's Case Dispositive Motion to Dismiss by Curia Global, Inc., Curia Missouri Inc.. (Viceconte, Christopher) (Entered: 06/15/2022) (4) |
| Jun 8, 2022 | 60 | [SEALED] Letter to The Honorable Christopher J. Burke from Christopher Viceconte regarding Reply Brief Requesting a Stay Pending the Outcome of Curia's Case Dispositive Motion to Dismiss - re 54 Letter, 55 MOTION to Stay re 54 Letter, to The Honorable Christopher J. Burke from Christopher Viceconte Requesting a Stay Pending the Outcome of Curia's Case Dispositive Motion to Dismiss. (Attachments: # 1 Certificate of Service)(Viceconte, Christopher) (Entered: 06/08/2022) (0) |
| Jun 3, 2022 | 59 | [SEALED] Letter to Honorable Christopher J. Burke from Robert M. Oakes regarding Opposition to Curia Motion to Stay - re 55 MOTION to Stay re 54 Letter, to The Honorable Christopher J. Burke from Christopher Viceconte Requesting a Stay Pending the Outcome of Curia's Case Dispositive Motion to Dismiss. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3)(Oakes, Robert) (Additional attachment(s) added on 6/3/2022: # 4 Exhibit 4) (dlb). (Entered: 06/03/2022) (0) |
| May 31, 2022 | 58 | REDACTED VERSION of 54 Letter, to The Honorable Christopher J. Burke from Christopher Viceconte regarding Requesting a Stay Pending the Outcome of Curia's Case Dispositive Motion to Dismiss by Curia Global, Inc., Curia Missouri Inc.. (Viceconte, Christopher) (Entered: 05/31/2022) (4) |
| May 30, 2022 | 57 | STIPULATION TO EXTEND TIME Plaintiffs response to Defendants' Motion to Stay and Reply thereto to June 3, 2022 and June 8, 2022 - filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 05/30/2022) (2) |
| May 27, 2022 | 56 | ORAL ORDER: The Court, having reviewed the pending motion to stay ("Motion"), (D.I. 55), hereby ORDERS as follows: (1) The Court will hear argument on the Motion on Monday, June 27, 2022 at 11:45 AM via teleconference.; (2) By no later than June 20, 2022, the parties shall jointly provide the Court's Courtroom Deputy, Ms. Benyo, with a dial-in number via e-mail to use for the call; and (3) It is possible that, prior to the teleconference, the Court will simply determine that it can decide the Motion on the papers, and in that event, it will cancel the teleconference. That said, the Court encourages (though it does not require) the parties to consider allowing a newer attorney who is familiar with the case and the Motion (if applicable) to argue the Motion. If any party advises the Court in advance that a newer attorney will argue the Motion, see Standing Order Regarding Courtroom Opportunities for Newer Attorneys, https://www.ded.uscourts.gov/sites/ded/files/StandingOrder2017.pdf, then the Court will go forward with the conference and will not cancel it. Ordered by Judge Christopher J. Burke on 5/27/2022. (dlb) (Entered: 05/27/2022) (0) |
| May 24, 2022 | 54 | [SEALED] Letter to The Honorable Christopher J. Burke from Christopher Viceconte regarding Requesting a Stay Pending the Outcome of Curia's Case Dispositive Motion to Dismiss - re 26 Opening Brief in Support, 25 MOTION to Dismiss for Failure to State a Claim MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter , 27 Declaration,. (Attachments: # 1 Certificate of Service)(Viceconte, Christopher) (Entered: 05/24/2022) (0) |
| May 24, 2022 | 55 | MOTION to Stay re 54 Letter, to The Honorable Christopher J. Burke from Christopher Viceconte Requesting a Stay Pending the Outcome of Curia's Case Dispositive Motion to Dismiss - filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Text of Proposed Order)(Viceconte, Christopher) (Entered: 05/24/2022) (Main Document) (2) |
| May 24, 2022 | 55 | MOTION to Stay re 54 Letter, to The Honorable Christopher J. Burke from Christopher Viceconte Requesting a Stay Pending the Outcome of Curia's Case Dispositive Motion to Dismiss - filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Text of Proposed Order)(Viceconte, Christopher) (Entered: 05/24/2022) (Text of Proposed Order) (2) |
| May 2, 2022 | 52 | REDACTED VERSION of 45 Reply Brief, in Further Support of Defendants' Motion to Dismiss Pursuant Rules 12(b)(1) and 12(b)(6) by Curia Global, Inc., Curia Missouri Inc.. (Viceconte, Christopher) (Entered: 05/02/2022) (16) |
| May 2, 2022 | 53 | REDACTED VERSION of 46 Declaration in Further Support of Defendants' Motion to Dismiss Pursuant Rules 12(b)(1) and 12(b)(6) by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Exhibit C)(Viceconte, Christopher) (Entered: 05/02/2022) (Main Document) (2) |
| May 2, 2022 | 53 | REDACTED VERSION of 46 Declaration in Further Support of Defendants' Motion to Dismiss Pursuant Rules 12(b)(1) and 12(b)(6) by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Exhibit C)(Viceconte, Christopher) (Entered: 05/02/2022) (Exhibit C) (4) |
| Apr 29, 2022 | 51 | REDACTED VERSION of (943 in 1:18-cv-01675-CFC-CJB) Letter, to The Honorable Christopher J. Burke from Christopher Viceconte in Further Opposition to Plaintiffs' Request for Premature Discovery by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Exhibit A)(Viceconte, Christopher) (Entered: 04/29/2022) (Main Document) (4) |
| Apr 29, 2022 | 51 | REDACTED VERSION of (943 in 1:18-cv-01675-CFC-CJB) Letter, to The Honorable Christopher J. Burke from Christopher Viceconte in Further Opposition to Plaintiffs' Request for Premature Discovery by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Exhibit A)(Viceconte, Christopher) (Entered: 04/29/2022) (Exhibit A) (3) |
| Apr 28, 2022 | 50 | REDACTED VERSION of (41 in 1:22-cv-00199-CFC-CJB, 942 in 1:18-cv-01675-CFC-CJB) Letter to Honorable Christopher J. Burke by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Oakes, Robert) (Entered: 04/28/2022) (Main Document) (5) |
| Apr 28, 2022 | 50 | REDACTED VERSION of (41 in 1:22-cv-00199-CFC-CJB, 942 in 1:18-cv-01675-CFC-CJB) Letter to Honorable Christopher J. Burke by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Oakes, Robert) (Entered: 04/28/2022) (Exhibit A) (12) |
| Apr 28, 2022 | 50 | REDACTED VERSION of (41 in 1:22-cv-00199-CFC-CJB, 942 in 1:18-cv-01675-CFC-CJB) Letter to Honorable Christopher J. Burke by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Oakes, Robert) (Entered: 04/28/2022) (Exhibit B) (17) |
| Apr 27, 2022 | 49 | ORAL ORDER: The Court, having reviewed the pending motion regarding a discovery and protective order dispute between Plaintiffs and Curia Missouri, Inc. and Curia Global, Inc. (collectively, "Curia," who are third parties in Civil Action No. 18-1675-CFC-CJB and Defendants in Civil Action No. 22-199-CFC-CJB), (Civil Action No. 18-1675-CFC-CJB, D.I. 937; Civil Action No. 22-199-CFC-CJB, D.I. 34), and the related briefing, (Civil Action No. 18-1675-CFC-CJB, D.I. 938, D.I. 939, D.I. 942, D.I. 943; Civil Action No. 22-199-CFC-CJB, D.I. 35, D.I. 36, D.I. 41, D.I. 42,), hereby ORDERS that Plaintiff's request to modify the protective order in the 18-1675 action to allow two documents to be used in the 22-199 action, or alternatively for the two documents to be produced via expedited discovery in the 22-199 action, is DENIED. Today's teleconference is hereby CANCELLED. The Court has considered the balancing test and various factors set out in Pansy v. Borough of Stroudsburg, 23 F.3d 772, 786-90 (3d Cir. 1994) as to the part of Plaintiffs' request that attempts to show good cause to modify the protective order in the 18-1675 case to allow for such use, and has considered the three good cause factors regarding provision of expedited discovery set out in Williams v. Ocwen Loan Servicing, LLC, Civil Action No. 14-1096-LPS-CJB, 2015 WL 184024, at *2 (D. Del. Jan. 13, 2015). Plaintiffs have not shown good cause, for the following reasons: (1) First and most importantly, the request is premised on the assertion that Plaintiffs need to use the two documents because the documents "unequivocally show that Curia is infringing an additional patent [the 595 patent.]" (D.I. 35 at 1) But Plaintiffs make no attempt at all to show the Court why the documents are relevant to the 22-199 case (i.e., what those two documents have to do with the infringement question as to the 595 patent, or how they might plausibly show such infringement). (D.I. 36 at 2; D.I. 41 at 2; D.I. 42 at 1) There would not be good cause to allow for use of the documents unless the documents were actually germane to a key question in the 22-199 case. Plaintiffs failure to explain why that is so alone dooms the request.; (2) Second, Plaintiffs have had the two documents for months; if the documents were so important, one would think Plaintiffs would have sought their use months ago. (D.I. 36 at 1, 2) Plaintiffs say they did not do so sooner because they did not become aware that Curia was infringing the 595 patent until recently. (D.I. 41 at 2) But Plaintiffs make no attempt to actually demonstrate to the Court how or why they only recently came to this realization.; and (3) Third, no preliminary injunction motion has yet been filed in the 22-199 case, and it is still uncertain if one will need to be filed and/or when it might need to be filed. If such a motion does ultimately need to be filed imminently, and Plaintiffs still do not have the ability to use the two documents at that point, then their ability to demonstrate good cause at that time might be stronger than it is now. Ordered by Judge Christopher J. Burke on 4/27/2022. Associated Cases: 1:18-cv-01675-CFC-CJB, 1:22-cv-00199-CFC-CJB(dlb) (Entered: 04/27/2022) (0) |
| Apr 26, 2022 | 47 | CERTIFICATE OF SERVICE of Declaration of Christopher Viceconte in Further Support of Defendants Motion to Dismiss pursuant to Rule 12(b)(1) and Rule 12(b)(6) by Curia Global, Inc., Curia Missouri Inc. re 46 Declaration (Viceconte, Christopher) (Entered: 04/26/2022) (2) |
| Apr 26, 2022 | 48 | REQUEST for Oral Argument by Curia Global, Inc., Curia Missouri Inc. re 25 MOTION to Dismiss for Failure to State a Claim MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter . (Viceconte, Christopher) (Entered: 04/26/2022) (1) |
| Apr 25, 2022 | 43 | REDACTED VERSION of 38 Answering Brief in Opposition, by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Oakes, Robert) (Entered: 04/25/2022) (30) |
| Apr 25, 2022 | 44 | REDACTED VERSION of 39 Declaration of Kelly A. Del Dotto by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Oakes, Robert) (Entered: 04/25/2022) (Main Document) (3) |
| Apr 25, 2022 | 45 | [SEALED] REPLY BRIEF re 25 MOTION to Dismiss for Failure to State a Claim MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Certificate of Compliance, # 2 Certificate of Service)(Viceconte, Christopher) (Entered: 04/25/2022) (0) |
| Apr 25, 2022 | 46 | [SEALED] DECLARATION re 45 Reply Brief, by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Exhibit C)(Viceconte, Christopher) (Entered: 04/25/2022) (0) |
| Apr 25, 2022 | 44 | REDACTED VERSION of 39 Declaration of Kelly A. Del Dotto by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Oakes, Robert) (Entered: 04/25/2022) (Exhibit 1) (9) |
| Apr 25, 2022 | 44 | REDACTED VERSION of 39 Declaration of Kelly A. Del Dotto by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Oakes, Robert) (Entered: 04/25/2022) (Exhibit 2) (3) |
| Apr 22, 2022 | 41 | [SEALED] Letter to Honorable Christopher J. Burke from Robert M. Oakes regarding response re Curia dispute - re (938 in 1:18-cv-01675-CFC-CJB, 35 in 1:22-cv-00199-CFC-CJB) Letter. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Oakes, Robert) (Entered: 04/22/2022) (0) |
| Apr 22, 2022 | 42 | [SEALED] Letter to The Honorable Christopher J. Burke from Christopher Viceconte regarding Further Opposition to Plaintiffs' Request for Premature Discovery - re 36 Letter,. (Attachments: # 1 Exhibit A, # 2 Certificate of Service)(Viceconte, Christopher) (Entered: 04/22/2022) (0) |
| Apr 21, 2022 | 40 | REDACTED VERSION of (35 in 1:22-cv-00199-CFC-CJB, 938 in 1:18-cv-01675-CFC-CJB) Letter by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Oakes, Robert) (Entered: 04/21/2022) (Main Document) (5) |
| Apr 21, 2022 | 40 | REDACTED VERSION of (35 in 1:22-cv-00199-CFC-CJB, 938 in 1:18-cv-01675-CFC-CJB) Letter by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Oakes, Robert) (Entered: 04/21/2022) (Exhibit 1) (12) |
| Apr 21, 2022 | 40 | REDACTED VERSION of (35 in 1:22-cv-00199-CFC-CJB, 938 in 1:18-cv-01675-CFC-CJB) Letter by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Oakes, Robert) (Entered: 04/21/2022) (Exhibit 2) (1) |
| Apr 21, 2022 | 40 | REDACTED VERSION of (35 in 1:22-cv-00199-CFC-CJB, 938 in 1:18-cv-01675-CFC-CJB) Letter by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Oakes, Robert) (Entered: 04/21/2022) (Exhibit 3) (1) |
| Apr 21, 2022 | 40 | REDACTED VERSION of (35 in 1:22-cv-00199-CFC-CJB, 938 in 1:18-cv-01675-CFC-CJB) Letter by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Oakes, Robert) (Entered: 04/21/2022) (Exhibit 4) (20) |
| Apr 21, 2022 | 40 | REDACTED VERSION of (35 in 1:22-cv-00199-CFC-CJB, 938 in 1:18-cv-01675-CFC-CJB) Letter by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Oakes, Robert) (Entered: 04/21/2022) (Exhibit 5) (21) |
| Apr 21, 2022 | 40 | REDACTED VERSION of (35 in 1:22-cv-00199-CFC-CJB, 938 in 1:18-cv-01675-CFC-CJB) Letter by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Oakes, Robert) (Entered: 04/21/2022) (Exhibit 6) (4) |
| Apr 18, 2022 | 38 | [SEALED] ANSWERING BRIEF in Opposition re 25 MOTION to Dismiss for Failure to State a Claim MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc..Reply Brief due date per Local Rules is 4/25/2022. (Del Dotto, Kelly) (Entered: 04/18/2022) (0) |
| Apr 18, 2022 | 39 | [SEALED] DECLARATION re 38 Answering Brief in Opposition, of Kelly A. Del Dotto by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2)(Del Dotto, Kelly) (Entered: 04/18/2022) (0) |
| Apr 14, 2022 | 35 | [SEALED] Letter to Honorable Christopher J. Burke from Kelly A. Del Dotto regarding Discovery Dispute. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6)(Del Dotto, Kelly) (Entered: 04/14/2022) (0) |
| Apr 14, 2022 | 36 | Letter to The Honorable Christopher J. Burke from Christopher Viceconte regarding Curia's Letter Brief in Opposition to Plaintiffs' Request for Premature Discovery - re (936 in 1:18-cv-01675-CFC-CJB) Order Setting Teleconference,,,,,,. (Attachments: # 1 Text of Proposed Order)(Viceconte, Christopher) (Entered: 04/14/2022) (Main Document) (5) |
| Apr 14, 2022 | 37 | [SEALED] PROPOSED ORDER Discovery Dispute regarding Curia re (939 in 1:18-cv-01675-CFC-CJB, 36 in 1:22-cv-00199-CFC-CJB) Letter, by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. (Del Dotto, Kelly) (Entered: 04/14/2022) (0) |
| Apr 14, 2022 | 36 | Letter to The Honorable Christopher J. Burke from Christopher Viceconte regarding Curia's Letter Brief in Opposition to Plaintiffs' Request for Premature Discovery - re (936 in 1:18-cv-01675-CFC-CJB) Order Setting Teleconference,,,,,,. (Attachments: # 1 Text of Proposed Order)(Viceconte, Christopher) (Entered: 04/14/2022) (Text of Proposed Order) (2) |
| Apr 11, 2022 | 34 | Joint MOTION to Resolve Discovery Dispute re (33 in 1:22-cv-00199-CFC-CJB) Order Setting Teleconference,,,,,, - filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc.. Motions referred to Christopher J. Burke.(Del Dotto, Kelly) (Entered: 04/11/2022) (2) |
| Apr 7, 2022 | 33 | ORAL ORDER Setting Teleconference: The Court has reviewed the parties' April 5, 2022 letter requesting a discovery dispute teleconference regarding several discovery disputes. (C.A. No. 18-1675, D.I. 935) It hereby ORDERS that the procedures for resolving a discovery dispute set out in the Scheduling Order will be modified as follows: (1) The parties shall file a joint "Motion for Teleconference to Resolve Discovery Dispute," the text of which can be found in the "Forms" tab of Judge Burke's page on the District Court's website.; (2) A discovery dispute teleconference is set for April 27, 2022 at 12:00 PM before Judge Christopher J. Burke.; (3) By April 14, 2022, each side should file with the Court a letter, not to exceed three (3) single-spaced pages, in no less than 12-point font, outlining the issues in dispute and their positions on those issues. By April 22, 2021, each side may file a letter, not to exceed two (2) single-spaced pages, in no less than 12-point font, in response.; (4) The parties should also consult and follow Judge Burke's "Guidelines for Discovery Disputes," which is found in the "Guidelines" tab on Judge Burke's portion of the District Court's website.; (5) By no later than April 25, 2022, the parties shall jointly provide the Court's Courtroom Deputy, Ms. Benyo, with a dial-in number via e-mail to use for the call; and (6) The Court may choose to resolve the disputes prior to the telephone conference and will, in that event, cancel the conference. Ordered by Judge Christopher J. Burke on 4/7/2022. Associated Cases: 1:18-cv-01675-CFC-CJB, 1:22-cv-00199-CFC-CJB(dlb) (Entered: 04/07/2022) (0) |
| Apr 6, 2022 | 31 | NOTICE of Appearance by Elizabeth M. Flanagan on behalf of Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc. (Flanagan, Elizabeth) (Entered: 04/06/2022) (2) |
| Apr 6, 2022 | 32 | NOTICE of Appearance by William Chad Shear on behalf of Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc. (Shear, William) (Entered: 04/06/2022) (2) |
| Apr 4, 2022 | 29 | MOTION for Pro Hac Vice Appearance of Attorney Kaitlin M. Abrams - filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification)(Viceconte, Christopher) (Entered: 04/04/2022) (Main Document) (1) |
| Apr 4, 2022 | 30 | MOTION for Pro Hac Vice Appearance of Attorney Chinmay P. Bagwe - filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification)(Viceconte, Christopher) (Entered: 04/04/2022) (Main Document) (1) |
| Apr 4, 2022 | 30 | MOTION for Pro Hac Vice Appearance of Attorney Chinmay P. Bagwe - filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification)(Viceconte, Christopher) (Entered: 04/04/2022) (Text of Proposed Order) (1) |
| Apr 4, 2022 | 30 | MOTION for Pro Hac Vice Appearance of Attorney Chinmay P. Bagwe - filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification)(Viceconte, Christopher) (Entered: 04/04/2022) (Certification) (1) |
| Apr 4, 2022 | 29 | MOTION for Pro Hac Vice Appearance of Attorney Kaitlin M. Abrams - filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification)(Viceconte, Christopher) (Entered: 04/04/2022) (Text of Proposed Order) (1) |
| Apr 4, 2022 | 29 | MOTION for Pro Hac Vice Appearance of Attorney Kaitlin M. Abrams - filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Text of Proposed Order, # 2 Certification)(Viceconte, Christopher) (Entered: 04/04/2022) (Certification) (1) |
| Apr 1, 2022 | 25 | MOTION to Dismiss for Failure to State a Claim , MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter - filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Text of Proposed Order)(Viceconte, Christopher) (Entered: 04/01/2022) (Main Document) (2) |
| Apr 1, 2022 | 26 | OPENING BRIEF in Support re 25 MOTION to Dismiss for Failure to State a Claim MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter filed by Curia Global, Inc., Curia Missouri Inc..Answering Brief/Response due date per Local Rules is 4/18/2022. (Attachments: # 1 Certification of Compliance)(Viceconte, Christopher) (Entered: 04/01/2022) (Main Document) (23) |
| Apr 1, 2022 | 27 | DECLARATION re 26 Opening Brief in Support, 25 MOTION to Dismiss for Failure to State a Claim MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter of Christopher Viceconte by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Viceconte, Christopher) (Entered: 04/01/2022) (Main Document) (2) |
| Apr 1, 2022 | 28 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Curia Global, Inc. for Curia Missouri Inc. filed by Curia Global, Inc., Curia Missouri Inc.. (Viceconte, Christopher) (Entered: 04/01/2022) (1) |
| Apr 1, 2022 | 25 | MOTION to Dismiss for Failure to State a Claim , MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter - filed by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Text of Proposed Order)(Viceconte, Christopher) (Entered: 04/01/2022) (Text of Proposed Order) (2) |
| Apr 1, 2022 | 27 | DECLARATION re 26 Opening Brief in Support, 25 MOTION to Dismiss for Failure to State a Claim MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter of Christopher Viceconte by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Viceconte, Christopher) (Entered: 04/01/2022) (Exhibit A) (4) |
| Apr 1, 2022 | 27 | DECLARATION re 26 Opening Brief in Support, 25 MOTION to Dismiss for Failure to State a Claim MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter of Christopher Viceconte by Curia Global, Inc., Curia Missouri Inc.. (Attachments: # 1 Exhibit A, # 2 Exhibit B)(Viceconte, Christopher) (Entered: 04/01/2022) (Exhibit B) (12) |
| Apr 1, 2022 | 26 | OPENING BRIEF in Support re 25 MOTION to Dismiss for Failure to State a Claim MOTION to Dismiss for Lack of Jurisdiction Over the Subject Matter filed by Curia Global, Inc., Curia Missouri Inc..Answering Brief/Response due date per Local Rules is 4/18/2022. (Attachments: # 1 Certification of Compliance)(Viceconte, Christopher) (Entered: 04/01/2022) (Certification of Compliance) (2) |
| Mar 30, 2022 | 24 | MOTION for Pro Hac Vice Appearance of Attorney Jason Leonard - filed by Astellas Pharma US, Inc., Astellas US LLC. (Del Dotto, Kelly) (Entered: 03/30/2022) (3) |
| Mar 29, 2022 | 23 | MOTION for Pro Hac Vice Appearance of Attorney Lisa M. Ferri and Manuel J. Velez - filed by Gilead Sciences, Inc.. (Del Dotto, Kelly) (Entered: 03/29/2022) (4) |
| Mar 24, 2022 | 22 | NOTICE OF SERVICE of Plaintiffs' First Set of Requests for Production of Document and Things (Nos.1-65) filed by Astellas Pharma US, Inc., Astellas US LLC, Gilead Sciences, Inc..(Del Dotto, Kelly) (Entered: 03/24/2022) (2) |
| Mar 23, 2022 | 21 | Amended Complaint* (1) |
